Skip to main content
. 2006 Sep;55(9):1255–1262. doi: 10.1136/gut.2005.081794

Table 3 Demographic data on 60 patients included in the two week efficacy analysis of tacrolimus (FK506) for treatment of ulcerative colitis (UC).

Variable High trough group Low trough group Placebo group p Value
No of patients 19 21 20
Sex (M/F) 9/10 11/10 9/11 0.890*
Age (y) (mean (SD)) 33.3 (10.3) 31.2 (10.8) 30.0 (6.4) 0.645†
Weight (kg) (mean (SD)) 53.0 (12.9) 50.9 (8.2) 53.6 (9.3) 0.758†
Disease duration (y) (mean (SD)) 7.0 (6.3) 4.8 (3.5) 6.0 (3.5) 0.470†
Extent of disease
 Pancolitis 12 14 10 0.522*
 Left sided 7 7 10
DAI total score
 6 0 2 1
 7–9 13 9 8
 10–12 6 10 11
 Mean (SD) 9.2 (1.2) 9.2 (1.8) 9.4 (1.5) 0.845†
Steroid resistant/dependent
 Resistant* 5 5 5 0.983*
 Dependent 14 16 15
Previous treatment (within 6 months)
 Azathioprine 5 1 2 0.150*
 Cytapheresis 4 4 7 0.445*
Concomitant medication
 Prednisolone (⩾10 mg/day) 19 21 20
 5‐Aminosalicylates 19 21 18 0.126*
 Immunosuppressants 0 0 0
 Cytapheresis 0 0 0

*Steroid resistance was defined as unresponsiveness to oral or intravenous corticosteroid therapy (equivalent to a daily dose of more than 30 mg of prednisolone) over at least 2 weeks.

2 test.

†Kruskal‐Wallis test.